GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » Cyclically Adjusted PS Ratio

icad (ICAD) Cyclically Adjusted PS Ratio : 0.72 (As of Apr. 28, 2024)


View and export this data going back to 1992. Start your Free Trial

What is icad Cyclically Adjusted PS Ratio?

As of today (2024-04-28), icad's current share price is $1.47. icad's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $2.05. icad's Cyclically Adjusted PS Ratio for today is 0.72.

The historical rank and industry rank for icad's Cyclically Adjusted PS Ratio or its related term are showing as below:

ICAD' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 0.52   Med: 1.66   Max: 8.36
Current: 0.72

During the past years, icad's highest Cyclically Adjusted PS Ratio was 8.36. The lowest was 0.52. And the median was 1.66.

ICAD's Cyclically Adjusted PS Ratio is ranked better than
80.22% of 465 companies
in the Medical Devices & Instruments industry
Industry Median: 2.11 vs ICAD: 0.72

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

icad's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.180. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $2.05 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


icad Cyclically Adjusted PS Ratio Historical Data

The historical data trend for icad's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

icad Cyclically Adjusted PS Ratio Chart

icad Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.05 5.51 3.03 0.80 0.87

icad Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 0.55 0.74 0.98 0.87

Competitive Comparison of icad's Cyclically Adjusted PS Ratio

For the Medical Devices subindustry, icad's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


icad's Cyclically Adjusted PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, icad's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where icad's Cyclically Adjusted PS Ratio falls into.



icad Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

icad's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=1.47/2.05
=0.72

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

icad's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, icad's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.18/129.4194*129.4194
=0.180

Current CPI (Dec. 2023) = 129.4194.

icad Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.745 99.695 0.967
201406 0.687 100.560 0.884
201409 0.769 100.428 0.991
201412 0.846 99.070 1.105
201503 0.847 99.621 1.100
201506 0.711 100.684 0.914
201509 0.609 100.392 0.785
201512 0.484 99.792 0.628
201603 0.382 100.470 0.492
201606 0.463 101.688 0.589
201609 0.376 101.861 0.478
201612 0.432 101.863 0.549
201703 0.421 102.862 0.530
201706 0.393 103.349 0.492
201709 0.426 104.136 0.529
201712 0.479 104.011 0.596
201803 0.381 105.290 0.468
201806 0.370 106.317 0.450
201809 0.371 106.507 0.451
201812 0.414 105.998 0.505
201903 0.394 107.251 0.475
201906 0.415 108.070 0.497
201909 0.407 108.329 0.486
201912 0.484 108.420 0.578
202003 0.325 108.902 0.386
202006 0.249 108.767 0.296
202009 0.308 109.815 0.363
202012 0.453 109.897 0.533
202103 0.361 111.754 0.418
202106 0.313 114.631 0.353
202109 0.374 115.734 0.418
202112 0.311 117.630 0.342
202203 0.299 121.301 0.319
202206 0.301 125.017 0.312
202209 0.173 125.227 0.179
202212 0.183 125.222 0.189
202303 0.229 127.348 0.233
202306 0.232 128.729 0.233
202309 0.159 129.860 0.158
202312 0.180 129.419 0.180

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


icad  (NAS:ICAD) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


icad Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of icad's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


icad (ICAD) Business Description

Traded in Other Exchanges
N/A
Address
98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.
Executives
Eric Lonnqvist officer: See Remarks 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea officer: See Remarks 2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go officer: Sr. VP of R&D C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno officer: See Remarks C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine director 82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish director 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton director C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood director 845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein director C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter officer: See Remarks C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens officer: Executive VP of Marketing C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado officer: Interim Chief FinancialOfficer 98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel director 15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard director C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831

icad (ICAD) Headlines